/
GOSS
$0.16+$0.01 (+4.46%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$76.7M
489M shares
52-week range
$0.14 – $3.87
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
9.30%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-7.96
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $114.7M | $48.5M |
| Cost of revenue | $297.0K | $3.1M | $4.3M | $0 | $0 | $0 | $0 | $1.0M |
| Gross profit | −$297.0K | −$3.1M | −$4.3M | $0 | $0 | $0 | $114.7M | $47.5M |
| Gross margin | — | — | — | — | — | — | 100.0% | 97.9% |
| R&D | $55.3M | $143.4M | $158.0M | $170.3M | $170.9M | $135.3M | $138.5M | $174.1M |
| Operating income | −$149.0M | −$186.1M | −$210.6M | −$216.1M | −$218.6M | −$183.8M | −$59.9M | −$163.3M |
| EBITDA | −$149.0M | −$179.4M | −$226.4M | −$209.4M | −$211.1M | −$161.9M | −$40.0M | −$158.5M |
| Net income | −$147.0M | −$180.8M | −$243.4M | −$234.0M | −$229.4M | −$179.8M | −$56.5M | −$170.4M |
| Net margin | — | — | — | — | — | — | -49.3% | -351.5% |
| EPS (diluted) | -2.43 | -3.30 | -3.67 | -3.33 | -2.84 | -1.18 | -0.25 | -0.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $36M | $-0.41 | $-0.57–$-0.24 | 5 |
| 2027 | $53M | $-0.10 | $-0.22–$0.01 | 5 |
| 2028 | $132M | $0.04 | $-0.46–$0.77 | 5 |
| 2029 | $242M | $0.19 | $0.07–$0.36 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.38
Price
$0.16
Implied upside
+739%
Peer comparison
Gossamer Bio, Inc. Common Stock
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
www.gossamerbio.com- Employees
- 162
- IPO / List date
- Feb 8, 2019
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds GOSS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,217,868 | $400.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GOSS yet.
